Roivant Sciences Ltd Ordinary Shares ROIV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
-
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
-
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
-
Roivant Provides Update on Graves’ Disease Development Program
-
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
-
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
-
Pfizer shares downgraded as patent expirations loom
-
Roivant Sciences shares drop as lupus treatment misses trial goal
Trading Information
- Previous Close Price
- $11.37
- Day Range
- $11.18–11.41
- 52-Week Range
- $8.25–13.06
- Bid/Ask
- $11.35 / $11.29
- Market Cap
- $8.34 Bil
- Volume/Avg
- 5.7 Mil / 6.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 59.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 908
- Website
- https://www.roivant.com
Comparables
Valuation
|
Metric
|
ROIV
|
KNSA
|
ABUS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 223.16 | — |
Price/Book Value | 1.53 | 4.01 | 6.01 |
Price/Sales | 59.62 | 5.19 | 67.82 |
Price/Cash Flow | — | 71.09 | — |
Price/Earnings
ROIV
KNSA
ABUS
Financial Strength
|
Metric
|
ROIV
|
KNSA
|
ABUS
|
|---|---|---|---|
Quick Ratio | 27.41 | 2.84 | 6.36 |
Current Ratio | 27.91 | 3.57 | 6.56 |
Interest Coverage | 114.28 | — | −495.55 |
Quick Ratio
ROIV
KNSA
ABUS
Profitability
|
Metric
|
ROIV
|
KNSA
|
ABUS
|
|---|---|---|---|
Return on Assets (Normalized) | −14.26% | 2.27% | −42.31% |
Return on Equity (Normalized) | −18.59% | 2.73% | −55.99% |
Return on Invested Capital (Normalized) | −18.38% | 2.66% | −60.24% |
Return on Assets
ROIV
KNSA
ABUS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rmndsznkx | Xsch | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qjsgbbnr | Rgklk | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tgxvwccn | Zykshqz | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jgxnmpn | Kcnpydv | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Smhgfrpmw | Zmxf | $32.8 Bil | |||
| BioNTech SE ADR
BNTX
| Flgpchqb | Jjygd | $28.3 Bil | |||
| Moderna Inc
MRNA
| Wwjhylxq | Grss | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Nkplrrgt | Sbspw | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tlfdqzpjx | Dmzwcyl | $13.3 Bil | |||
| Incyte Corp
INCY
| Nypzwpsrb | Hqnjwzh | $13.0 Bil |
United States